Abstract
Type 2 diabetes mellitus is a heterogeneous disease and using the current therapeutic means, it is not always possible to achieve the target levels of compensation. For that reason, new variations of the already established preparations are being developed (insulin degludec, lixisenatide - a GLP1 receptor agonist) and new ways of utilising already known therapeutic goals are being researched (chimeric peptids, non-peptid activators of insulin receptors or GLP1 receptors, glitazars).
There are also whole new options being discovered for hyperglycaemia treatment (glucokinase activators, SGLT-2 inhibitors, inhibitors of type 1 11ß-hydroxysteroid dehydrogenase). It is thus possible to expect new options in pharmacotherapy of type 2 diabetes in the near future.